Skip to main content
Macrogen, Inc. logo

Macrogen, Inc. — Investor Relations & Filings

Ticker · 038290 ISIN · KR7038290003 KO Professional, scientific and technical activities
Open in API
Filings indexed 352 across all filing types
Latest filing 2022-02-28 AGM Information
Country KR South Korea
Listing KO 038290

About Macrogen, Inc.

https://www.macrogen.com/en/main

Macrogen, Inc. is a biotechnology company specializing in precision medicine and genomic analysis. It provides a comprehensive suite of services, including Next-Generation Sequencing (NGS), Sanger sequencing, and spatial transcriptome analysis, to a global client base. The company's core activities are focused on three key areas: Research and Data Analysis, offering fast and accurate genomic services to the scientific community; Clinical Diagnostics, advancing disease prediction through the integration of genomic and medical big data; and Personal Healthcare, providing genetic tests for wellness, nutrition, and disease risk assessment. By combining its extensive genomic expertise with big data and AI, Macrogen aims to deliver hyper-personalized healthcare solutions and innovate in the field of future medicine.

Recent filings

Filing Released Lang Actions
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Macrogen. It outlines the date, location, and agenda items for the upcoming meeting, including the approval of financial statements and the appointment of directors. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2022-02-28 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company (Macrogen) is holding its AGM on a date that coincides with other companies' meetings. Since this is a regulatory disclosure regarding the scheduling and compliance of a shareholder meeting rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2022-02-28 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically marked as a '정정신고' (Amendment Report). It details changes to stock option grants, including the number of recipients and the number of shares, which falls under the category of capital structure and share-related changes. Since it is a formal regulatory filing regarding share-based compensation and capital adjustments that does not fit into specific categories like 'Director's Dealing' or 'Share Issue', it is best classified as a Regulatory Filing (RNS).
2022-02-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by executives to report changes in their shareholdings, which corresponds to the 'Director's Dealing' category.
2022-02-23 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Macrogen regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the approval process by the board of directors. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2022-02-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Macrogen) announcing a significant change (over 30%) in sales or profit structure. This is a standard periodic financial disclosure required by the Korea Exchange (KRX) when financial results deviate significantly from the previous period. It provides key financial highlights (revenue, operating profit, net income) and the reasons for the change. Since it is an initial announcement of financial results rather than a full annual report or a transcript, it falls under the 'Earnings Release' category. FY 2021
2022-02-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.